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Abstract
Bluetongue (BT) is a noncontagious, insect-transmitted disease of ruminants caused by the bluetongue virus (BTV). A
laboratory animal model would greatly facilitate the studies of pathogenesis, immune response and vaccination against
BTV. Herein, we show that adult mice deficient in type I IFN receptor (IFNAR
(2/2)) are highly susceptible to BTV-4 and BTV-8
infection when the virus is administered intravenously. Disease was characterized by ocular discharges and apathy, starting
at 48 hours post-infection and quickly leading to animal death within 60 hours of inoculation. Infectious virus was
recovered from the spleen, lung, thymus, and lymph nodes indicating a systemic infection. In addition, a lymphoid
depletion in spleen, and severe pneumonia were observed in the infected mice. Furthermore, IFNAR
(2/2) adult mice
immunized with a BTV-4 inactivated vaccine showed the induction of neutralizing antibodies against BTV-4 and complete
protection against challenge with a lethal dose of this virus. The data indicate that this mouse model may facilitate the
study of BTV pathogenesis, and the development of new effective vaccines for BTV.
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Introduction
Bluetongue (BT) is an infectious noncontagious viral disease of
ruminants caused by the bluetongue virus (BTV). The virus,
consisting of 24 different serotypes, is transmitted to its vertebrate
host by a few species of biting midges of the Culicoides genus
(Diptera: Ceratopogonidae) [1]. BT is a reportable disease of
considerable socioeconomic concern and of major importance in
the international trade of animals and animal products. From
1998 through 2005, at least 6 BTV strains belonging to 5 serotypes
(BTV-1, BTV-2, BTV-4, BTV-9, and BTV-16) were continously
present in the Mediterranean Basin [2,3,4]. Since August 2006,
BTV-8 has caused severe epizootic outbreakes in northern Europe
[5]. The emergence of BT in parts of Europe never before affected
was attributed mainly to climate change and linked to the
Northern expansion of the major Old World vector Culicoides
imicola. Additionally, there is also evidence for the involvement of
other novel indigenous European vector species of Culicoides (C.
obsoletus and C. pulicaris ) [6].
BTV has a genome composed of ten linear segments of double-
stranded RNA (dsRNA) and is classified as the type species of the
genus Orbivirus within the family Reoviridae [7]. The BTV genome
encodes 7 structural (VP1 through VP7) and 4 nonstructural
proteins (NS1 through NS3/NS3A). The outer capsid is composed
of two major structural proteins, VP2 and VP5 (segments 2 and 6,
respectively), involved in cell attachment and virus entry. VP2 is
known to contain the major neutralization determinant of BTV
while VP5 influences virus neutralization through its conforma-
tional interaction with VP2 [8]. The outer capsid covers the inner
capsid that is composed of two major structural proteins VP3 and
VP7 (encoded by segments 3 and 7, respectively) and three distinct
minor proteins (VP1, VP4, and VP6 corresponding to segments 1,
4, and 9 respectively) [9], in addition to the viral genome. Four
other nonstructural proteins, produced during the viral cycle (NS1,
NS2, and NS3/NS3A) (segments 6, 8, and 10 respectively), are
more conserved among serotypes [10].
Studies involving the natural hosts of BTV are limited by the
complexity of the system, the scarce knowledge of their immune
system, and the need to have an animal facility with biosafety level
3. To circumvent some of these problems, an adequate system
would be the use of adult mice because of the knowledge of its
genetics and its manageability. BTV infects newborn mice
[11,12,13], but an adult mouse model will be necessary to allow
studiesofacquiredimmune responsesandvaccinationagainst BTV.
Bluetongue virus is a potent interferon alpha (IFN-a) inducer
[14,15,16]. In addition, a temporal relationship between viremia and
IFN-a activity has been observed in sheep infected with BTV, where
IFN peak concentrations induced approximately a 90% decrease in
virus titer [17]. IFN-a plays an essential role in the antiviral innate
immune response. Virus-derived dsRNAs are detected by Toll-like
receptors on type I IFN-producing cells (mostly notably on
plasmacytoid dendritic cells). Secreted IFNs bind to the type I IFN
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Janus kinase (Jak)/signal transducer and activator of transcription
(Stat) signalling pathway. This in turn induces the transcriptional
activation of target genes, the products of which render the cells
resistant to virus replication through various mechanisms, including
degradation of viral mRNAs, inhibition of viral translation, and
inhibition of cell growth [18,19,20,21]. Blocking IFN-a/b activity in
mice leads to a dramatically increased sensitivity to many viruses.
Geneticallytargeted (knockout) mice lacking the bsubunit of the IFN-
a/b receptor (IFNAR
(2/2) mice) are unable to establish an antiviral
state and, as a consequence, are highly susceptible to many viral
infections, despite the presence of an otherwise intact immune system
[20,22]. Recently, Ida-Hosonumaet al [23] found that the deletion of
the IFNAR gene in the IFNAR
(2/2)mice resulted in the disruptionof
IFN- a/b-induced signaling, which is an important determinant of
the tissue tropism and pathogenicity of poliovirus. Similarly, it has
been reported that IFN- a/b plays an important role in the
pathogenicity and tissue tropism of some viruses. The lack of an IFN
system allows the virus to replicate more efficiently and IFNAR
(2/2)
mice have been used as a laboratory animal model to study the
immune response and pathogenicity of coronaviruses, vaccinia virus
Ankara strain (MVA), measles virus, Rift valley fever virus and West
Nile virus [24,25,26,27]. All these data, and the presence of an
otherwise intact immune system in these mice [20,22] suggest that
IFNAR
(2/2) mice could be a good animal model to study BTV
infections and to evaluate vaccine strategies against this virus.
Here, we report the establishment of a new laboratory animal
model suitable for the evaluation of vaccination strategies against
BTV. Adult IFNAR
(2/2) mice support the in vivo growth of BTV-4
after intravenous inoculation. BTV-4 replicated in spleen, lung,
thymus, and lymph nodes (popliteal, inguinal, mediastinal, and
mesenteric) of IFNAR
(2/2) mice reproducing the tropism
observed during calf and sheep infections. In addition, IF-
NAR
(2/2) mice vaccinated with a BTV-4 inactivated vaccine
show complete protection against a lethal dose of BTV-4
Results
BTV-4 causes a lethal infection in adult IFNAR
(2/2) mice
In order to develop an adult murine model for BTV infection in
which mice showed disease symptoms, we tested the susceptibility of
C57BL/6 and IFNAR
(2/2) mice to BTV infection. Since blood is
the natural route of BTV infection in ruminants, adult C57BL/6
and IFNAR
(2/2) mice (males, 8 weeks old) were infected
intravenously (i.v.) with 10
6 PFUs of BTV-4. Under these
conditions, C57BL/6 mice did not show any disease symptom or
death following viral infection. By contrast, IFNAR
(2/2) mice were
susceptible to BTV-4 infection (Fig. 1A), showing disease symptoms
characterized by ocular discharges and apathy starting at 48 h.p.i.
Disease progression led to animal death within 60 h.p.i. The LD50
value was obtained by i.v. inoculation with 10-fold dilutions of
BTV-4, resulting in a LD50 value of 10
2.6 PFU (Fig. 1B). At low
infectious doses (10
2 PFU or less) mice survived up to 21 days, at
which point the experiment was terminated (data not shown).
To determine virus dissemination, viral titers in blood samples
after i.v. inoculation with 10
4 PFUs of BTV-4 were analyzed.
According to the previous data, no viremia was detected in
C57BL/6 mice (data not shown). In contrast, viremia was
observed in IFNAR
(2/2) mice at day 2 post-infection (Fig. 2A),
with peak titers of 5610
4 PFU/ml at day 4 post-infection (p.i.),
before animal death. IFNAR
(2/2) mice inoculated with 10
2 PFU
did not show any viremia but titers up to 3610
4 PFU/ml were
observed at 3 and 4 days p.i. in mice inoculated with 10
3 PFUs.
Viral spread was determined in tissue samples. The first tissue to
be reached by the virus was the spleen (Fig. 2B) where infectious
virus was detected as early as 24 h.p.i. (5610
3 PFU/gr), with viral
titers increasing thereafter until death (reaching titers of 2610
6
PFU/gr). By 48 h.p.i. significant titers of BTV-4 were detected in
spleen, lung, thymus, and popliteal and mesenteric lymph nodes.
At 72 h.p.i., titers up to 10
6 PFU/gr of BTV-4 were recovered
from the spleen, lung, thymus, and lymph nodes (popliteal,
inguinal, mediastinal and mesenteric). No infectious virus was
detected in liver, brain, heart, tongue, skin, and testicles at any
time points examined, even when the tissues were analyzed by
RT-PCR (data not shown). Interestingly, the virus was not
detected in the blood until 48 h.p.i. These results suggest that the
virus leaks into the blood stream after replicating in the spleen.
Susceptibility of IFNAR
(2/2) mice to other BTV serotypes
To determine whether IFNAR
(2/2) mice were susceptible to
BTV of different serotypes, IFNAR
(2/2) mice were inoculated
with ten-fold serial dilutions of BTV-8. Mice infected with serotype
8 showed similar symptoms to those shown after infection with
serotype 4. However, BTV-8 showed higher virulence than BTV-4
with only 10 PFUs of BTV-8 being enough to kill 100% of the
mice at day 7 p.i. (Fig. 3A), while BTV-4 was not lethal at the same
infective dose (Fig. 1B). The viremia was determined after i.v.
inoculation with 10-fold dilutions of BTV-8 (Fig. 3B). BTV-8 was
first detected in blood of mice inoculated with 10 PFUs at day 4
post-infection, and the titer increased up to 2610
4 PFU/ml at day
5 p.i. Titers up to 8610
3 PFU/ml were observed at 3 and 4 days
p.i. in mice infected with 10
3 and 10
2 PFUs, respectively. In the
three dilutions of virus analyzed, viral titers increased thereafter
until animal death. Although BTV-8 showed higher virulence than
BTV-4 in IFNAR
(2/2) mice, BTV-8 and BTV-4 titers in blood
were equivalent, indicating that the higher virulence of serotype 8
is not due to a higher level of viral replication. These data suggest
that IFNAR
(2/2) mice could be an adequate small animal model
to study differences in virulence among BTV serotypes.
BTV-4 infection of IFNAR
(2/2) adult mice causes
microscopic lesions in several tissues
In order to study the pathological effects of the infection in the
organs where BTV replicates, histological analysis were performed
on material of several organs extracted from BTV infected and
uninfected IFNAR
(2/2) mice at 48 h.p.i. Gross pathological
alterations were characterized by widespread oedema, haemor-
rhages especially in spleen and lungs, and enlarged spleen and
lymph nodes. Histological examination of lungs of BTV infected
mice showed hyperemia and increased septum size with infiltration
of lymphocytes, inactivated macrophages and a few neutrophils
(Fig. 4). The peribronchial and perivascular connective tissue
contained a few infiltrating round cells (Fig. 4). These histopatho-
logical findings are consistent with bronchointerstitial pneumonia.
There was also a moderate oedema in the alveolar cavity with
presence of abundant alveolar macrophages and a few detached
epithelial cells (descamative alveolitis). The infected spleen showed a
marked lymphoid depletion with infiltration of neutrophils in the
whitepulp (Fig.4).Thislymphoiddepletionwasalso observedinthe
thymus as well as the loss of thymic architecture with the medulla
and the cortex becoming not distinguishable (data not shown). The
results suggest that BTV-4 produces similar tissue lesions in
IFNAR
(2/2) mice than in the natural host.
Immunized IFNAR
(2/2) mice are completely protected
against a lethal BTV-4 challenge
All the previous data indicated that BTV-4 caused a lethal
infection in adult IFNAR
(2/2) mice. To provide further proof that
Murine Model for BTV Infection
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animals and that IFNAR
(2/2) mice are a good animal model for
BTV vaccination studies, vaccination protection experiments were
performed. Adult IFNAR
(2/2) mice were immunized with a
ZULVAC-BTV-4 inactivated BTV-4 preparation. The vaccine
was administered by two consecutive subcutaneous injections of
the equivalent to 3610
5 TCID50 of BTV-4 at 3 weeks intervals.
After the second immunization, VP2 antibody titers were
determined by ELISA. All immunized animals, but not the
control animals, developed an antibody response (Fig. 5A)
indicating a successful immunization. In addition, the immuniza-
tion induced neutralizing antibodies against BTV-4 in IFNAR
(2/
2) mice (VNT 1.5360.32) as detected by virus neutralization tests.
Three weeks after the second immunization, immunized and
control IFNAR
(2/2) mice were challenged intravenously with 10
3
PFUs of BTV-4. While all nonimmunized animals died, 100% of
the immunized animals were protected against a lethal challenge
(Fig. 5B). Infectious viral titers were analyzed in the blood of
immunized and nonimmunized IFNAR
(2/2) mice by plaque assay
after intravenous infection with BTV-4 (Fig. 5C). No Infectious
viruses were detected in immunized mice; however, we observed
titers up to 3610
4 PFU/ml in nonimmunized animals at day 5
post-challenge. In addition, we analyzed by RT-qPCR the
presence of BTV genomes in the blood of inmmunized and
nonimmunized IFNAR
(2/2) mice challenged with BTV-4. The
results are summarized in Table 1. BTV genomes were readily
detected in nonimmunized mice at days three and four after BTV
infection (Ct: 27–29) and increased (Ct: 23–26) thereafter until the
Figure 1. Susceptibility of adult mice to BTV-4 infection. (A) C57BL/6 and IFNAR
(2/2) mice (8 weeks old, 6 mice per group) were intravenously
inoculated with 10
6 PFUs of BTV-4. The mice were observed every 12 h for the first 3 days and every 24 h for 7 days. (B) Survival rates of IFNAR
(2/2)
mice after inoculation with BTV-4. Mice (8 weeks old, 6 mice per group) were intravenously inoculated with 10-fold dilutions of BTV-4. The number of
PFUs inoculated is indicated on each survival group. The mice were observed every 24 h for 7 days.
doi:10.1371/journal.pone.0005171.g001
Murine Model for BTV Infection
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positive results for the majority of the immunized mice (n=5) at all
days post-challenge analyzed (Ct$38). Viral genomes were
detected in one of the vaccinated mice (Ct: 30) at days four and
five post-challenge and in two of them at day 5 (Ct: 32). However,
in these three immunized mice the Ct was higher than in the
nonimmunized mice and the presence of BTV-genomes reverted
to negative at day 7 post-challenge. Overall, these data indicate
that protective immunity was achieved after vaccination. These
results confirm that BTV-4 was the causative agent of disease and
death of adult IFNAR
(2/2) mice.
Discussion
For years, different groups have tried to establish a laboratory
animal model to facilitate the studies of pathogenesis, immune
response and vaccination against BTV. Natural hosts, although
excellent tools for studies of pathogenesis and vaccination, are
Figure 2. BTV-4 titers in blood and several organs of infected IFNAR
(2/2) mice. (A) Titers of BTV-4 recovered in blood after intravenous
infection with 10
2 (&), 10
3(N), or 10
4 (m) PFUs of BTV-4. Virus was extracted from blood and determined as described in Materials and Methods. Each
point represents the mean values of the viral titer of six animals, and standard deviations are shown as error bars. (B) Mice (8 weeks old, 6 mice per
group) were inoculated intravenously with 10
4 PFUs of BTV-4. Virus was extracted from the indicated tissues at 24, 48 and 72 hours after infection for
virus titration. Standard deviations are given. Procedures are detailed in Materials and methods.
doi:10.1371/journal.pone.0005171.g002
Murine Model for BTV Infection
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characterize a new animal model based on adult IFNAR
(2/2)
mice that support the in vivo growth of BTV-4 and BTV-8 after
intravenous inoculation. A tremendous advantage of this mouse
model is the availability of a wide variety of reagents that can be
used to study many aspects of the immune response to the virus. In
addition, we propose this animal model as an adequate system for
testing BTV vaccines, an important issue because the cost of
testing new vaccines in target species is a major obstacle for
laboratories and industries. The new mouse model for the study of
BTV infection has unique features that open the possibility to
study in the same host-virus system susceptibility, virulence,
immunobiology of infection, and vaccine efficacy, in ways that are
not approachable with the natural host.
BTV infects newborn mice [11,12,13,28], but an adult animal
model will be necessary to allow studies of acquired immune
responses and vaccination against BTV. Different approaches
have been followed to avoid this problem. The protective effects of
baculovirus expressed BTV-10 minor and non-structural proteins
were assessed by measuring virus titers in the ovaries of mice
challenged with homologous recombinant vaccinia virus (rVV).
Protection mediated by CTLs specific for the BTV minor or
nonstructural proteins could not be evaluated by challenging mice
with BTV-10, as the virus does not cause disease in adult mice
[29]. The infection of fetal mice with BTV leads to severe cerebral
malformation. Infection of 2-week-old mice resulted in very
limited multiplication without sequelae, and infection of 4-week-
old mice did not show clinical disease and no viral multiplication
Figure 3. Survival rates of IFNAR
(2/2) mice and virus titers in blood after inoculation with BTV-8. (A) Mice (8 weeks old, 6 mice per
group) were intravenously inoculated with 10-fold dilutions of BTV-8. The number of PFUs inoculated is indicated on each survival group. The mice
were observed every 24 h for 7 days. (B) Titers of BTV-8 recovered in blood after intravenously infection with 10-fold dilutions of BTV-4. The number
of PFUs inoculated is indicated on each survival group. Virus was extracted from blood and determined as described in Materials and Methods. Each
point represents the mean values of the viral titer of six animals, and standard deviations are shown as error bars.
doi:10.1371/journal.pone.0005171.g003
Murine Model for BTV Infection
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pathologies that do not resemble those found in the natural host.
Another aspect to consider is the route of inoculation that may
determine the outcome of infection. In this work, we have used the
intravenous inoculation to resemble the natural infection route by
mosquito biting. Thus, mice infected with BTV i.v. develop
clinical symptoms, as it happens in natural hosts. This makes the
mouse model even more atractive to be used as a tool for studying
immune response to BTV and vaccination strategies.
Up-regulation of type I IFN is one of the earliest cellular
responses upon contact with infectious agents. The rapid induction
of type I IFN reflects the crucial role that this cytokine plays in the
inhibition of viral spread before the generation of a specific
immune response. Given that viruses must at least partially
circumvent the IFN response, it is not surprising that an inability
to do this can restrict host range. There are many examples where
this is known. For example, neither measles virus nor polio virus
will replicate efficiently in mouse models unless the IFN system has
been compromised [24,31]. BTV is a potent type I interferon
inducer in mice and cattle [14,16,32]. Our results show that BTV
is pathogenic for IFNAR
(2/2) mice mainly due to the lack of the
IFN-I receptor, allowing the virus to circumvent the IFN-I
response in the host. In addition, IFNAR
(2/2) mice serve as a
good animal model for BTV, reproducing many aspects of its
natural host infection. First, IFNAR
(2/2) mice infected with BTV
showed viremia and disease symptoms, in contrast with C57BL/6
mice, which did not show them, even when these animals were
infected at the highest viral dose tested (10
6 PFUs/mouse). The
appearance of viremia after inoculation in infected IFNAR
(2/2)
mice was dependent on the viral dose, althought the highest titers
observed in blood were not dose-dependent. Second, the
differential virulence of serotypes 4 and 8 were maintained in
this animal model. Some BTV serotypes such as serotype 8, which
recently caused infection in northern Europe, exhibit enhanced
virulence in cattle [5], in contrast to BTV-4 that usually exhibits
subclinical infections in this species. In infected IFNAR
(2/2) mice,
BTV-8 killed 100% of the animals with a dose as low as 10 PFUs
per mouse. In contrast 10
3 PFUs of BTV-4 were needed to kill
100% of the mice. In addition, the virus titers found in the blood of
infected mice were similar at the same virus doses for the animals
infected with BTV-8 than with BTV-4, indicating that BTV-8
exhibited a higher virulence than BTV-4 in the IFNAR
(2/2)
model, as is observed in cattle, one of the BTV natural hosts.
Third, BTV dissemination in IFNAR
(2/2) mice reproduced BTV
infection in cattle and sheep. High titers of BTV are present in the
lungs, precapsular and mesenteric lymph nodes, thymus, and
spleen of infected calves [33,34]. In IFNAR
(2/2) mice, the virus
was detected in spleen before was isolated from other organs,
including blood. Release of BTV from spleen was followed by an
increased in viremia and dissemination to other organs (lymph
nodes, lung and thymus), followed by its dissemination to lymph
nodes, lung, and thymus after intravenous infection. This has been
Figure 4. Tissue sections of lung and spleen from BTV-4 infected adult IFNAR
(2/2) mice. Mice were infected with 10
3 PFUs of BTV-4
intravenously. Tissues were harvested at 48 h.p.i.. Hematoxylin and eosin staining are shown. Lungs of BTV-infected mice show hyperemia and
increased size of the interalveolar septa (1006). The spleen sections of BTV-infected mice show loss of architectural structure and marked lymphoid
depletion (1006).
doi:10.1371/journal.pone.0005171.g004
Murine Model for BTV Infection
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pattern in IFNAR
(2/2) mice. Histological analyses of BTV
infected mice at 48 h.p.i. showed many similarities with lessions
described in natural hosts. The permeability disorders of the
vascular system described for ruminants [35] is reflected in the
petecheias observed in spleen in BTV infected mice. The
enlargement of lymph nodes reflects an ongoing immune response.
However, the observed lymphoid depletion suggests that other
cells are migrating to these organs or that a general aedema results
in organ enlargement. The lungs are especially susceptible to
permeability disorders of the vasculature induced by BTV, and
this is consistent in BTV infected mice as well as in ruminants. In
general, pathology in natural hosts has not been profoundly
studied. The described pathology similarities between IFNAR
(2/2)
mice and ruminants after infection with BTV indicate that our
mouse model may be a good tool to study new findings in BTV
pathology.
The cost of testing new vaccines in target species is a major
obstacle for laboratories and industries. For this reason, the
intracerebral inoculation of newborn mice with BTV vaccines has
been used as an animal model to evaluate the level of attenuation
of live attenuated BTV vaccines [28]. Our results show that adult
IFNAR
(2/2) mice serve as a good animal model to test BTV
vaccines. Even though the lack of type I interferon signals may
have an effect in the development of acquired immune responses,
our results and previous studies [20,22,24,25,26,27] show that the
IFNAR
(2/2) infection model is useful for the definition of effective
vaccine candidates against BTV. Indeed, in our study all
immunized animals developed an antibody response specific of
BTV-4 with the production of neutralizing antibodies against the
same serotype, indicating a successful immunization. The
protection mediated by inactivated whole BTV vaccine in
IFNAR
(2/2) mice infected with a lethal dose of BTV-4 was
complete, and 100% of the animals did not show any symptoms
associated with infection or died. Viremia was not detected in the
blood of immunized animals after challenge with BTV-4 when
analyzed by plaque assay. The presence of BTV genomes in the
blood of immunized mice after BTV-4 challenge analyzed by RT-
qPCR, a more sensible method than the plaque assay, showed the
presence of viral genomes in the blood of some of the immunized
mice but in all the cases, the Cts were higher than in the
nonimmunized mice and those that were RT-qPCR positive
reverted to negative at day seven post-challenge. Similar RTqPCR
results have been observed in cattle and sheep vaccinated with
ZULVAC-BTV-4 inactivated BTV-4 preparation [36] These
Figure 5. Protection of vaccinated IFNAR
(2/2) mice against a
lethal BTV-4 challenge. Mice (8 weeks old, 8 per group) were
immunized twice by subcutaneous administration of an inactivated
BTV-4 vaccine and inoculated with 10
3 PFUs of BTV-4,. (A) ELISA
detection of antibodies to BTV-4 VP2 in serum of immunized and
nonimmunized IFNAR
(2/2) mice. Serum was collected two days before
the challenge with BTV-4, and dilutions (1:50 to 1:1350) were analyzed
by ELISA as described in Materials and Methods. (B) Survival rates of
immunized and nonimmunized IFNAR
(2/2) mice after inoculation with
BTV-4. The mice were observed every 24 h for 14 days. (C) Titers of BTV-
4 recovered in blood of immunized and nonimmunized IFNAR
(2/2) mice
after challenge with BTV-4. Virus was extracted from blood and
determined as described in Materials and Methods. Each point
represents the mean values of the viral titer of eight animals, and
standard deviations are shown as error bars.
doi:10.1371/journal.pone.0005171.g005
Table 1. Detection of BTV-4 in blood of immunized and
nonimmunized IFNAR
(2/2) mice after challenge with BTV-4 by
RT-qPCR_S5.
Animals Days post-challenge
34571 0
C-1 29.07 25.05 {
C-2 neg. 27.38 23.78 {
C-3 29.75 26.80 {
C-4 neg. 27.57 23.45 {
I-1 neg. neg. neg. neg. neg.
I-2 neg. 30.57 30.74 neg. neg.
I-3 neg. neg. neg. neg. neg.
I-4 neg. neg. neg. neg. neg.
I-5 neg. neg. neg. neg. neg.
I-6 neg. neg. neg. neg. neg.
I-7 neg. neg. 31.94 neg. neg.
I-8 neg. neg. 32.06 neg. neg.
Results expressed as Ct and transferred to negative (neg.) according to the cut-
off Ct$38 described by Toussaint et al. (2007).
I, immunized mice. C, nonimmunized mice.
{, death mice.
doi:10.1371/journal.pone.0005171.t001
Murine Model for BTV Infection
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pathological processes described in this work and, moreover,
suggest that the mouse model is adequate to evaluate vaccine
candidates. Future work will determine whether the ability to
protect mice with other vaccine formulations mimics the capacity
to protect the natural host.
In summary, we have characterized a novel small animal model
for BTV infection based on IFNAR
(2/2) adult mice that
reproduces many aspects of its natural host infection. This animal
model may facilitate the understanding of the mechanisms of BTV
pathogenicity in its natural host and a faster advance in the
development of new BTV vaccines.
Materials and Methods
Virus and cells
Baby hamster kidney cells (BHK-21), and Vero cells were grown
in Dulbecco’s modified Eagle’s medium (DMEM) supplemented
with2mMglutamineand10%fetalcalfserum(FCS).Standardvirus
titrations were performed in Vero cells. BTV serotypes 4 (Spain/01)
and 8 (Belgium/06), originally isolated from an infected sheep in
Spain in 2001 and a calf in Belgium in 2006, respectively, were used
in the experiments. Virus stocks were generated by infection of
confluent BHK-21 cells using a multiplicity of infection (MOI) of 1.
At 48 h.p.i. or when total cytopathic efect (CPE) was visible, the cells
and supernatants were harvested and centrifuged. The virus was
released from the cells by three freeze and thaw cycles.
Mice
C57BL/6 mice were purchased from Harlan Interfauna Ibe ´rica
S.L. IFN a/bR
o/o IFNAR
(2/2) mice [20], on a C57BL/6 genetic
background, were generously provided by Professor R. Zinkernagel
(Institute of Experimental Medicine, Zurich). All mice used were
matched for sex and age (males 8 weeks). Mice were maintained
under pathogen-free conditions and allowed to acclimatize to the
biosafety level 3 (BSL3) animal facility at the Centro de
Investigacio ´n en Sanidad Animal, INIA, Madrid, for 1 week before
use in our experiments. All experiments with live animals were
performed under the guidelines of the European Community (86/
609) and were approved by the site ethical review committee.
Animal inoculation and processing of samples
Mice were infected intravenously with different doses of virus.
Mice were examined for clinical symptoms daily. LD50 values were
calculated by the method of Reed and Muench (1938) [37], after
inoculation of mice with 10-fold serial dilutions of virus (from 10
6 to
10
1 PFU/mouse). Whole blood was collected in EDTA from all
animals at regular intervals after inoculation. At varying times post-
infection, several mice were sacrificed by perfusion with phosphate-
buffered saline(PBS),andseveralorgans(spleen,lung,thymus,liver,
brain, heart, tongue, skin, and testicles), and lymph nodes (popliteal,
inguinal, mediastinal, and mesenteric) were harvested. Tissues were
homogenized in PBS using a Tissue Lyser homogenizer (Quiagen).
The viruses were released from whole blood and homogenized
tissues by three freeze/thaw cycles. The amount of infectious virus
was measured by plaque assay on Vero cells.
Murine immunizations
Groups of 6 IFNAR
(2/2) mice were immunized by two
consecutive subcutaneous injections of either ZULVAC-BTV-4
(1.5610
6 TCID50BTV-4) inactivated BTV-4 preparation (Fort
Dodge Veterinaria, S.A.) or phosphate-buffered saline (PBS)
(controls), administered 3 weeks apart. Mice were intravenously
inoculated with 10
3 PFUs of BTV-4 (lethal dose) 3 weeks after the
last immunization. Mice were bled before each immunization and
virus challenge. Sera were tested for BTV-4 neutralizing
antibodies by Virus Neutralization Test (VNT).
Histopathology
Samples from different tissues and organs were taken and fixed
in 10% buffered formalin (pH 7.2) for histopathological studies.
After fixation, samples were dehydrated through a graded series of
alcohol to xylol and embedded in paraffin wax. Sections of 4-im-
thick were cut and stained with hematoxylin and eosin (H & E) for
histopathological analyses.
BTV-VP2 antibody detection by indirect ELISA
MaxiSorp plates (Nunc, USA) were coated with VP2 baculo-
virus expressed protein (164 ng per well) and incubated overnight
at 4uC. Plates were saturated with blocking buffer (PBS-0.05%
Tween 20 and 5% skimmed milk). The animal sera, diluted in
blocking buffer were added and incubated for 1 hour at 37uC.
After three washes in PBS-0.05% Tween 20, plates were incubated
for 1 hour at 37uC with an anti-mouse-HRP secondary antibody
(Biorad, USA) at a 1/2,000 dilution in blocking buffer. Finally,
after three washes in PBS-0.05% Tween 20, the reaction was
developed with 50 ml of substrate solution 3,39, 5,59–tetramethyl-
bencidine liquidsupersensitive (TMB) (Sigma) and stopped by
adding 50 mlo f3 NH 2SO4. Results were expressed as optical
densities (ODs) measured at 450 nm.
BTV-4 neutralizing antibody detection in immunized
mice by virus neutralizing test (VNT)
The VNT was used to determine neutralizing antibody titers
against BTV-4. For plaque reduction assays, 2 fold dilutions of
sera were mixed with 100 PFU of BTV-4, incubated for 1 hour at
37uC and then plated onto monolayers of Vero cells. After 1 hour,
agar overlays were added and the plates were incubated for
5 days. The titer was determined as the highest dilution that
reduced the number of plaques by 50%.
RT-qPCR specific for BTV segment 5
Whole blood was collected in EDTA from all animals at regular
intervals after inoculation and BTV challenge. Total RNA was
extracted from blood with TRI Reagent Solution (Ambion),
according to the method recommended by the manufacturer. The
real-time RT-qPCR specific for BTV segment 5 was performed as
described by Toussaint et al. (2007) [38].
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